YARDLEY, Pa., August 24, 2026--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at the ERS Congress in Barcelona, Spain, September 5-9, 2026.
This is the newest page. Registered accounts read further back.